Quadrivalent Human Papillomavirus Vaccine Initiation, Coverage, and Compliance Among U.S. Active Component Service Women, 2006-2011
Abstract
Human papillomavirus (HPV)is the most common sexually transmitted pathogen detected among U.S. service members. An estimated 169,682 incident diagnoses of HPV infection occurred between 2004-2009 among active component U.S. service members (rate of 2,306 cases per 100,000 person years). In 2006, a 3-dose HPV quadrivalent vaccine (HPV4), which protects against common HPV strains (types 6, 11, 16, 18) responsible for about 70 percent of cervical cancers and 80 percent of genital warts was licensed in the United States. Consistent with the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommendations the Department of Defense (DoD) has made the HPV4 vaccine available to all eligible service members aged 17-26 years. Th e ACIP has recommended administration of the second dose of vaccine 2 months aft er the first dose and the third dose at six months after the first dose.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2012
- Accession Number
- ADA564994
Entities
People
- Angelia Eick-cost
- Hala Maktabi
- Joel G. Gaydos
- Sharon L. Ludwig
- Uma D. Yerubandi
Organizations
- Armed Forces Health Surveillance Center